Sorafenib exerts anti-glioma activity in vitro and in vivo

Neuroscience Letters

Volumn 478, Issue 3, 2010, Pages 165-170

  Siegelin, Markus D ^a   Raskett, Christopher M ^a   Gilbert, Candace A ^a   Ross, Alonzo H ^a   Altieri, Dario C ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Apoptosis; Autophagy; Glioma; Sorafenib; Stat3

Indexed keywords

CYCLIN D; CYCLIN E; PROTEIN KINASE B; SORAFENIB; STAT3 PROTEIN; ANTINEOPLASTIC AGENT; BENZENESULFONIC ACID DERIVATIVE; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE; PROTEIN KINASE INHIBITOR; PYRIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER INHIBITION; CONTROLLED STUDY; FEMALE; GLIOMA; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IC 50; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MITOSIS INDEX; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; TUMOR XENOGRAFT; ANALOGS AND DERIVATIVES; ANIMAL; BRAIN NEOPLASMS; CANCER TRANSPLANTATION; CELL PROLIFERATION; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; EVALUATION STUDY; GLIOBLASTOMA; METABOLISM; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; PHYSIOLOGY; RANDOMIZATION; TREATMENT OUTCOME; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; AUTOPHAGY; BENZENESULFONATES; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLIOBLASTOMA; GLIOMA; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN KINASE INHIBITORS; PYRIDINES; RANDOM ALLOCATION; TREATMENT OUTCOME; NIACINAMIDE; PHENYLUREA COMPOUNDS;

EID: 77953611845     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2010.05.009     Document Type: Article

References (26)

1. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008, 455:1061-1068.
2. Abou-Alfa G.K. Selection of patients with hepatocellular carcinoma for sorafenib. J. Natl. Compr. Cancer Netw. 2009, 7:397-403.
3. Blechacz B.R., Smoot R.L., Bronk S.F., Werneburg N.W., Sirica A.E., Gores G.J. Sorafenib inhibits signal transducer and activator of transcription-3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2. Hepatology 2009, 50:1861-1870.
4. Brantley E.C., Nabors L.B., Gillespie G.Y., Choi Y.H., Palmer C.A., Harrison K., Roarty K., Benveniste E.N. Loss of protein inhibitors of activated STAT-3 expression in glioblastoma multiforme tumors: implications for STAT-3 activation and gene expression. Clin. Cancer Res. 2008, 14:4694-4704.
5. Dasgupta A., Raychaudhuri B., Haqqi T., Prayson R., Van Meir E.G., Vogelbaum M., Haque S.J. Stat3 activation is required for the growth of U87 cell-derived tumours in mice. Eur. J. Cancer 2009, 45:677-684.
6. de Groot J.F., Fuller G., Kumar A.J., Piao Y., Eterovic K., Ji Y., Conrad C.A. Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. Neurol. Oncol. 2010, 12:233-242.
7. Dehdashti A.R., Hegi M.E., Regli L., Pica A., Stupp R. New trends in the medical management of glioblastoma multiforme: the role of temozolomide chemotherapy. Neurosurg. Focus 2006, 20:E6.
8. Gaiser T., Becker M.R., Meyer J., Habel A., Siegelin M.D. p53-mediated inhibition of angiogenesis in diffuse low-grade astrocytomas. Neurochem. Int. 2009, 54:458-463.
9. Jiang H., White E.J., Conrad C., Gomez-Manzano C., Fueyo J. Autophagy pathways in glioblastoma. Methods Enzymol. 2009, 453:273-286.
10. Kang B.H., Plescia J., Song H.Y., Meli M., Colombo G., Beebe K., Scroggins B., Neckers L., Altieri D.C. Combinatorial drug design targeting multiple cancer signaling networks controlled by mitochondrial Hsp90. J. Clin. Invest. 2009, 119:454-464.
11. Kim S., Yazici Y.D., Calzada G., Wang Z.Y., Younes M.N., Jasser S.A., El-Naggar A.K., Myers J.N. Sorafenib inhibits the angiogenesis and growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice. Mol. Cancer Ther. 2007, 6:1785-1792.
12. Lefranc F., Brotchi J., Kiss R. Possible future issues in the treatment of glioblastomas: special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis. J. Clin. Oncol. 2005, 23:2411-2422.
13. Li A., Walling J., Kotliarov Y., Center A., Steed M.E., Ahn S.J., Rosenblum M., Mikkelsen T., Zenklusen J.C., Fine H.A. Genomic changes and gene expression profiles reveal that established glioma cell lines are poorly representative of primary human gliomas. Mol. Cancer Res. 2008, 6:21-30.
14. Liu L., Cao Y., Chen C., Zhang X., McNabola A., Wilkie D., Wilhelm S., Lynch M., Carter C. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res. 2006, 66:11851-11858.
15. Miller A.A, Murry D.J., Owzar K., Hollis D.R., Kennedy E.B., Abou-Alfa G., Desai A., Hwang J., Villalona-Calero M.A., Dees E.C., Lewis L.D., Fakih M.G., Edelman M.J., Millard F., Frank R.C., Hohl R.J., Ratain M.J. Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301. J. Clin. Oncol. 2009, 27:1800-1805.
16. Muldoon L.L., Soussain C., Jahnke K., Johanson C., Siegal T., Smith Q.R., Hall W.A., Hynynen K., Senter P.D., Peereboom D.M., Neuwelt E.A. Chemotherapy delivery issues in central nervous system malignancy: a reality check. J. Clin. Oncol. 2007, 25:2295-2305.
17. Pignochino Y., Grignani G., Cavalloni G., Motta M., Tapparo M., Bruno S., Bottos A., Gammaitoni L., Migliardi G., Camussi G., Alberghini M., Torchio B., Ferrari S., Bussolino F., Fagioli F., Picci P., Aglietta M. Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways. Mol. Cancer 2009, 8:118.
18. Plescia J., Salz W., Xia F., Pennati M., Zaffaroni N., Daidone M.G., Meli M., Dohi T., Fortugno P., Nefedova Y., Gabrilovich D.I., Colombo G., Altieri D.C. Rational design of shepherdin, a novel anticancer agent. Cancer Cell 2005, 7:457-468.
19. Rahaman S.O, Harbor P.C., Chernova O., Barnett G.H., Vogelbaum M.A., Haque S.J. Inhibition of constitutively active Stat3 suppresses proliferation and induces apoptosis in glioblastoma multiforme cells. Oncogene 2002, 21:8404-8413.
20. Ramakrishnan V., Timm M., Haug J.L., Kimlinger T.K., Wellik L.E., Witzig T.E., Rajkumar S.V., Adjei A.A., Kumar S. Sorafenib a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs. Oncogene 2010, 29:1190-1202.
21. Rosato R.R., Almenara J.A., Coe S., Grant S. The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation. Cancer Res. 2007, 67:9490-9500.
22. Wang Z., Zhou J., Fan J., Qiu S.J., Yu Y., Huang X.W., Tang Z.Y. Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma. Clin. Cancer Res. 2008, 14:5124-5130.
23. Wei J., Barr J., Kong L.Y., Wang Y., Wu A., Sharma A.K., Gumin J., Henry V., Colman H., Priebe W., Sawaya R., Lang F.F., Heimberger A.B. Glioblastoma cancer-initiating cells inhibit T-cell proliferation and effector responses by the signal transducers and activators of transcription 3 pathway. Mol. Cancer Ther. 2010, 9:67-78.
24. Wilhelm S.M., Carter C., Tang L., Wilkie D., McNabola A., Rong H., Chen C., Zhang X., Vincent P., McHugh M., Cao Y., Shujath J., Gawlak S., Eveleigh D., Rowley B., Liu L., Adnane L., Lynch M., Auclair D., Taylor I., Gedrich R., Voznesensky A., Riedl B., Post L.E., Bollag G., Trail P.A. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004, 64:7099-7109.
25. Yang F., Van Meter T.E., Buettner R., Hedvat M., Liang W., Kowolik C.M., Mepani N., Mirosevich J., Nam S., Chen M.Y., Tye G., Kirschbaum M., Jove R. Sorafenib inhibits signal transducer and activator of transcription 3 signaling associated with growth arrest and apoptosis of medulloblastomas. Mol. Cancer Ther. 2008, 7:3519-3526.
26. Yu C., Friday B.B., Lai J.P., Yang L., Sarkaria J., Kay N.E., Carter C.A., Roberts L.R., Kaufmann S.H., Adjei A.A. Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways. Mol. Cancer Ther. 2006, 5:2378-2387.